- BNF:
- 10.1.3
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- May 2013
Comments
RED:
- NICE TA373 for treating juvenile idiopathic arthritis (JIA). NHSE commissioned. (Decision date - January 2016)
- NICE TA375*: for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Replaces TA280) (Decision date - February 2016)
*Local agreement for abatacept use as monotherapy for patients with severe RA and interstitial lung disease. (Decision date - February 2022)
- For severe treatment-resistant morphoea (localised scleroderma) (adults and children 2 years and over). NHSE commissioned (Decision date - September 2021)
- Abatacept for refractory idiopathic inflammatory myopathies (adults and children aged 2 and over). NHSE commissioned. (Decision date - February 2022
DO NOT PRESCRIBE (DNP)
- NICE TA568: for treating psoriatic arthritis after DMARDS. (Terminated appraisal) (Decision date -April 2019)
- NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again